SG11201906229QA - Anti-ccr7 antibody drug conjugates - Google Patents
Anti-ccr7 antibody drug conjugatesInfo
- Publication number
- SG11201906229QA SG11201906229QA SG11201906229QA SG11201906229QA SG11201906229QA SG 11201906229Q A SG11201906229Q A SG 11201906229QA SG 11201906229Q A SG11201906229Q A SG 11201906229QA SG 11201906229Q A SG11201906229Q A SG 11201906229QA SG 11201906229Q A SG11201906229Q A SG 11201906229QA
- Authority
- SG
- Singapore
- Prior art keywords
- novartis
- institute
- genomics
- san diego
- dba
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 5
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 7
- 101100008681 Glycine max DHPS1 gene Proteins 0.000 abstract 7
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 229920000134 Metallised film Polymers 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000002020 sage Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
MeanTumor Vo lume { mm 15 2:3 2.5 30 4Dose2 WV psi* 11 054 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT omit °nolo milli offi mm11E11111° oimIE (10) International Publication Number WO 2018/142322 Al (51) International Patent Classification: CO7K 16/28 (2006.01) A61K 39/395 (2006.01) A61K 47/68 (2017.01) (21) International Application Number: PCT/IB2018/050639 (22) International Filing Date: 01 February 2018 (01.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/454,476 03 February 2017 (03.02.2017) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: BENDER, Steven; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). CHARLTON, Tracy; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). GALKIN, Anna; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop- kins Drive, San Diego, California 92121 (US). GEIERS- TANGER, Bernhard Hubert; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). GLASER, Scott Martin; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foun- dation, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). KASIBHATLA, Shailaja; 13073 Dres- sage Lane, San Diego, California 92130 (US). KNUTH, Mark; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). ROTTMANN, Sabine; c/o Novartis In- stitute for Functional Genomics, Inc., dba Genomics Insti- tute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). RUE, (54) Title: ANTI-CCR7 ANTIBODY DRUG CONJUGATES Days post-implant •••• No treatment hIgG1-CysMab.DAPA MPET-DM4 5mg/kg ▪ 121612.CysMab.DAPA.MPET.DM4 0.5 mg/kg -10- 121G12.CysMab.DAPA.MPET.DM4 2 mg/kg ▪ 121612.CysMab.DAPA.MPET.DM4 5 mg/kg \"ztv . 121G12.DAPA.sSPDB.DM4 0.5 mg/kg 121612.DAPA.sSPDB.DM4 2 mg/kg 121612.DAPA.sSPDB.DM4 5 mg/kg Figure 10 I I - (57) : This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding © fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents. O [Continued on next page] WO 2018/142322 Al MIDEDIMOMOIDEIREEMOMMIEMIMOHOIRVOIMIE Sarah; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). SPRAGGON, Glen; c/o Novartis Insti- tute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop- kins Drive, San Diego, California 92121 (US). UNO, Tet- suo; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(i)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762454476P | 2017-02-03 | 2017-02-03 | |
PCT/IB2018/050639 WO2018142322A1 (en) | 2017-02-03 | 2018-02-01 | Anti-ccr7 antibody drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906229QA true SG11201906229QA (en) | 2019-08-27 |
Family
ID=61283268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906229QA SG11201906229QA (en) | 2017-02-03 | 2018-02-01 | Anti-ccr7 antibody drug conjugates |
Country Status (25)
Country | Link |
---|---|
US (2) | US11634497B2 (en) |
EP (1) | EP3577139A1 (en) |
JP (1) | JP7312111B2 (en) |
CN (1) | CN110248963B (en) |
AR (1) | AR110920A1 (en) |
AU (1) | AU2018215701B2 (en) |
BR (1) | BR112019015950A2 (en) |
CA (1) | CA3049639A1 (en) |
CL (1) | CL2019002144A1 (en) |
CO (1) | CO2019008209A2 (en) |
CR (1) | CR20190346A (en) |
CU (1) | CU24648B1 (en) |
EA (1) | EA201991763A1 (en) |
EC (1) | ECSP19054235A (en) |
IL (1) | IL267834B2 (en) |
JO (1) | JOP20190187A1 (en) |
MA (1) | MA51778A (en) |
MX (2) | MX2019009119A (en) |
MY (1) | MY194997A (en) |
PE (1) | PE20191328A1 (en) |
PH (1) | PH12019501773A1 (en) |
SG (1) | SG11201906229QA (en) |
TW (1) | TW202323292A (en) |
UY (1) | UY37591A (en) |
WO (1) | WO2018142322A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190187A1 (en) * | 2017-02-03 | 2019-08-01 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
KR20190122739A (en) | 2017-02-28 | 2019-10-30 | 시애틀 지네틱스, 인크. | Cysteine Modified Antibodies for Conjugation |
KR20240015162A (en) | 2018-12-21 | 2024-02-02 | 어비디티 바이오사이언시스 인크. | Anti-transferrin receptor antibodies and uses thereof |
MX2022004379A (en) * | 2019-10-09 | 2022-07-19 | Catapult Therapeutics B V | Use of an anti-ccr7 antibody in combination therapies with a btk inhibitor and/or bcl2- inhibitor for treating hematological malignancies. |
JP2022553390A (en) * | 2019-10-25 | 2022-12-22 | ウーシー バイオロジクス アイルランド リミテッド | Novel anti-CD47 antibody and use thereof |
AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
JP2023527638A (en) | 2020-03-27 | 2023-06-30 | アビディティー バイオサイエンシーズ,インク. | Compositions and methods for treating facioscapulohumeral muscular dystrophy |
US20230181756A1 (en) * | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
MX2023001163A (en) | 2020-07-27 | 2023-02-22 | Tuojie Biotech Shanghai Co Ltd | Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof. |
US20240002509A1 (en) * | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
KR20230152032A (en) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | Binding agents and how to use them |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
KR20230161759A (en) * | 2022-05-19 | 2023-11-28 | 국민대학교산학협력단 | Antibodies regulating functions of a CC chemokine receptor 7 |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
ATE37983T1 (en) | 1982-04-22 | 1988-11-15 | Ici Plc | DELAYED RELEASE AGENT. |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (en) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | LIPOSOMAS COUPLING METHOD. |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JPH07503145A (en) | 1992-11-17 | 1995-04-06 | イコス コーポレイション | Novel 7-transmembrane receptor |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
JP2000507912A (en) | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | Sustained release composition of active agent |
ES2395214T3 (en) | 1996-03-04 | 2013-02-11 | The Penn State Research Foundation | Materials and methods to increase cellular internalization |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
DE69732306T2 (en) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | PREPARATION OF PARTICLE MEDICINES FOR INHALATION |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69833755T2 (en) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6043551A (en) | 1997-09-30 | 2000-03-28 | Intel Corporation | Metal locking structures to prevent a passivation layer from delaminating |
SE512663C2 (en) | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
US6153441A (en) | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
CA2335105C (en) | 1998-07-22 | 2010-05-11 | Osprey Pharmaceuticals Limited | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
WO2000009151A1 (en) | 1998-08-17 | 2000-02-24 | Schering Corporation | Regulation of dendritic cell trafficking |
US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
AU765588C (en) | 1999-11-24 | 2004-12-16 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
MXPA02005199A (en) | 1999-11-24 | 2002-11-07 | Schering Corp | Methods of inhibiting metastasis. |
DE60031793T2 (en) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | DOXORUBICIN AND DAUNORUBICIN-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE |
AU2001280891A1 (en) | 2000-08-01 | 2002-02-13 | Schering Corporation | Uses of mammalian genes and related reagents |
US6411163B1 (en) | 2000-08-14 | 2002-06-25 | Intersil Americas Inc. | Transconductance amplifier circuit |
AU2002251913A1 (en) | 2001-02-02 | 2002-08-19 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
JP2004535157A (en) | 2001-02-28 | 2004-11-25 | プロテイン デザイン ラブス, インコーポレイテッド | Chemokine receptors and diseases |
US20020168358A1 (en) | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
KR100635703B1 (en) | 2001-06-07 | 2006-10-17 | 케모센트릭스, 인크. | Cell Migration Assay |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
DE60324964D1 (en) | 2002-07-15 | 2009-01-08 | Univ Princeton | IAP-BINDING CONNECTIONS |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
WO2004104574A2 (en) | 2003-05-23 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7) |
ITRM20030386A1 (en) | 2003-08-05 | 2005-02-06 | Istituto Naz Per Le Malattie Infettive Lazz | METHOD AND DIAGNOSTIC TESTS BASED ON THE CITOFLUORIMETRIC ANALYSIS OF ANTIGEN-SPECIFIC T LYMPHOCYTES. |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
MXPA06008095A (en) | 2004-01-16 | 2007-03-28 | Univ Michigan | Conformationally constrained smac mimetics and the uses thereof. |
WO2005069888A2 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
DK2253614T3 (en) | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP inhibitors |
US7274964B2 (en) | 2004-04-16 | 2007-09-25 | Bal Seal Engineering Co., Inc. | Use of an axial canted coil spring as an electrical contact to minimize resistivity variations under dynamic loads |
EP1778718B1 (en) | 2004-07-02 | 2014-10-08 | Genentech, Inc. | Inhibitors of iap |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
JP2008505976A (en) | 2004-07-12 | 2008-02-28 | アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド | Tetrapeptide analogs |
US7456209B2 (en) | 2004-07-15 | 2008-11-25 | Tetralogic Pharmaceuticals Corporation | IAP binding compounds |
WO2006056061A1 (en) | 2004-11-24 | 2006-06-01 | Val-Chum, S.E.C. | Methods to identify, prepare, and use naive t cell recent thymic emigrants |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
ATE477254T1 (en) | 2004-12-20 | 2010-08-15 | Genentech Inc | PYRROLIDINES AS INHIBITORS OF IAP |
AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
CA2601243A1 (en) | 2005-03-09 | 2006-09-21 | Board Of Regents, The University Of Texas System | Methods and composition related to in vivo imaging of gene expression |
JP4361545B2 (en) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | Cancer treatment method using human monoclonal antibody and anti-PD-1 antibody alone or in combination with other immunotherapy against Programmed Death 1 (PD-1) |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2007005605A2 (en) | 2005-07-01 | 2007-01-11 | Washington University In St. Louis | Phosphospecific chemokine receptor antibodies |
WO2007003216A1 (en) * | 2005-07-06 | 2007-01-11 | Universidad Autónoma de Madrid | Anti-ccr7 receptor antibodies for the treatment of cancer |
PL1928503T3 (en) | 2005-08-24 | 2012-12-31 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
EP1928912A4 (en) | 2005-09-07 | 2010-02-24 | Medimmune Inc | Toxin conjugated eph receptor antibodies |
EP1937311A2 (en) | 2005-09-30 | 2008-07-02 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for modulating immune tolerance |
WO2007048022A2 (en) | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
WO2007055823A2 (en) | 2005-10-28 | 2007-05-18 | Multispan, Inc. | Gpcr expressing cell lines and antibodies |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
WO2008015694A2 (en) | 2006-05-23 | 2008-02-07 | V. B. Medicare Pvt. Ltd. | Recovery of dimethylformamide and other solvents from process streams of manufacture of trichlorogalactosucrose |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
KR20090130849A (en) | 2006-12-29 | 2009-12-24 | 오스프리 파마슈티컬스 유에스에이 인코퍼레이티드 | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
EP2148858A4 (en) | 2007-04-30 | 2011-01-26 | Genentech Inc | Inhibitors of iap |
PL2170959T3 (en) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
CL2008002687A1 (en) | 2007-09-12 | 2009-01-16 | Genentech Inc | Use of a pharmaceutical combination of a compound derived from thieno [3,2-d] pyrimidine with a chemotherapeutic agent in the treatment of a hyperproliferative disorder; pharmaceutical kit. |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
EP2073009A1 (en) | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
AU2009213738B2 (en) | 2008-02-11 | 2015-01-22 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
CN104524592B (en) | 2008-04-30 | 2018-06-05 | 伊缪诺金公司 | Crosslinking agent and their purposes |
EP2285403A2 (en) | 2008-05-14 | 2011-02-23 | Msm Protein Technologies, Inc. | Human monoclonal antibodies against human chemokine receptor ccr7 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
KR20110050529A (en) | 2008-08-25 | 2011-05-13 | 앰플리뮨, 인크. | Compositions of pd-1 antagonists and methods of use |
EA201170375A1 (en) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | PD-1 ANTAGONISTS AND METHODS OF THEIR APPLICATION |
EP2376535B9 (en) | 2008-12-09 | 2017-09-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2010127069A1 (en) * | 2009-04-29 | 2010-11-04 | Schering Corporation | Antibody purification |
US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
CN104984360A (en) | 2009-06-03 | 2015-10-21 | 伊缪诺金公司 | Conjugation methods |
RU2012101999A (en) | 2009-06-22 | 2013-07-27 | МЕДИММЬЮН, ЭлЭлСи | Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION |
EP2272977A1 (en) | 2009-07-08 | 2011-01-12 | Universite Libre De Bruxelles | Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome |
US8276780B2 (en) | 2009-11-18 | 2012-10-02 | Snyder Industries, Inc. | Fitting torque arm restraint |
JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
WO2011123903A1 (en) | 2010-04-08 | 2011-10-13 | Adelaide Research & Innovation Pty Ltd | Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof |
CN105884895B (en) * | 2010-09-28 | 2019-12-13 | 株式会社Nb健康研究所 | Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier |
UY33826A (en) | 2010-12-22 | 2012-07-31 | Abbott Lab | UNION PROTEINS WITH TRIVARIABLE DOMAINS AND ITS USES |
UY33827A (en) | 2010-12-22 | 2012-07-31 | Abbott Lab | MEDIUM-IMMUNOGLOBULIN UNION PROTEINS AND ITS USES |
WO2012148547A1 (en) | 2011-02-24 | 2012-11-01 | The Schepens Eye Research Institute, Inc. | Compositions and methods for treating inflammatory conditions of the ocular surface |
PT2691155T (en) | 2011-03-29 | 2019-02-19 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
KR20140019415A (en) | 2011-03-29 | 2014-02-14 | 이뮤노젠 아이엔씨 | Process for manufacturing conjugates of improved homogeneity |
ES2760300T3 (en) | 2011-06-13 | 2020-05-13 | Tla Targeted Immunotherapies Ab | Diagnosis and treatment of inflammatory bowel disease and irritable bowel syndrome |
CN103857421B (en) | 2011-06-13 | 2017-09-22 | Tla指标免疫疗法公司 | The method for the treatment of cancer and the binding reagents used wherein |
WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
WO2012172346A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating respiratory conditions |
RU2011130448A (en) | 2011-07-22 | 2013-01-27 | Зао "Евроген" | METHODS AND KITS FOR INCREASING T-CELL DIVERSITY |
SG190466A1 (en) | 2011-11-18 | 2013-06-28 | Agency Science Tech & Res | Methods for diagnosis and/or prognosis of ovarian cancer |
EP2814525A1 (en) | 2012-02-13 | 2014-12-24 | Cook Medical Technologies LLC | Medical devices for collecting pathogenic cells |
WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
US9585970B2 (en) | 2012-06-04 | 2017-03-07 | Novartis Ag | Site-specific labeling methods and molecules produced thereby |
WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
US20150307619A1 (en) | 2012-12-13 | 2015-10-29 | The Schepens Eye Research Institute, Inc. | Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors |
KR102447350B1 (en) | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | Specific sites for modifying antibodies to make immunoconjugates |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
EP2961434A2 (en) * | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
WO2014153114A1 (en) | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
JP6333943B2 (en) * | 2013-03-15 | 2018-05-30 | ノバルティス アーゲー | Antibody drug conjugate |
JP6469644B2 (en) | 2013-03-15 | 2019-02-13 | アムジエン・インコーポレーテツド | Methods and compositions related to anti-CCR7 antigen binding proteins |
US9719504B2 (en) | 2013-03-15 | 2017-08-01 | Integrated Designs, L.P. | Pump having an automated gas removal and fluid recovery system and method |
SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
GB201315748D0 (en) | 2013-09-04 | 2013-10-16 | Imp Innovations Ltd | Biological methods and materials for use therein |
WO2015033137A1 (en) | 2013-09-04 | 2015-03-12 | Imperial Innovations Limited | Biological methods and materials for use therein |
GB2518221A (en) | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
WO2015095301A2 (en) | 2013-12-17 | 2015-06-25 | Irm Llc | Cytotoxic peptides and conjugates thereof |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
CA2940451A1 (en) | 2014-03-12 | 2015-09-17 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
US10758568B2 (en) | 2014-04-16 | 2020-09-01 | Genovie Ab | Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract |
HUE056023T2 (en) * | 2014-05-22 | 2022-01-28 | Byondis Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
JP6681346B2 (en) | 2014-06-13 | 2020-04-15 | ノバルティス アーゲー | Auristatin derivative and its conjugate |
GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
MX2017006301A (en) * | 2014-11-14 | 2017-08-21 | Novartis Ag | Antibody drug conjugates. |
EP3623573A1 (en) * | 2014-12-17 | 2020-03-18 | National Oilwell DHT, L.P. | Method of pressure testing a wellbore |
WO2016179472A2 (en) | 2015-05-07 | 2016-11-10 | University Of Maryland, Baltimore | Modulation of natural killer cell tolerance |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
EP3411965B1 (en) * | 2016-02-01 | 2020-04-08 | Telefonaktiebolaget LM Ericsson (publ) | Reconfigurable optical modulator |
JOP20190187A1 (en) * | 2017-02-03 | 2019-08-01 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
-
2017
- 2017-06-16 JO JOP/2019/0187A patent/JOP20190187A1/en unknown
-
2018
- 2018-02-01 JP JP2019541414A patent/JP7312111B2/en active Active
- 2018-02-01 EA EA201991763A patent/EA201991763A1/en unknown
- 2018-02-01 CR CR20190346A patent/CR20190346A/en unknown
- 2018-02-01 PE PE2019001507A patent/PE20191328A1/en unknown
- 2018-02-01 IL IL267834A patent/IL267834B2/en unknown
- 2018-02-01 CA CA3049639A patent/CA3049639A1/en active Pending
- 2018-02-01 WO PCT/IB2018/050639 patent/WO2018142322A1/en unknown
- 2018-02-01 AR ARP180100236A patent/AR110920A1/en unknown
- 2018-02-01 US US16/482,173 patent/US11634497B2/en active Active
- 2018-02-01 CN CN201880009163.2A patent/CN110248963B/en active Active
- 2018-02-01 BR BR112019015950A patent/BR112019015950A2/en unknown
- 2018-02-01 TW TW111137885A patent/TW202323292A/en unknown
- 2018-02-01 EP EP18707417.4A patent/EP3577139A1/en active Pending
- 2018-02-01 MA MA051778A patent/MA51778A/en unknown
- 2018-02-01 CU CU2019000072A patent/CU24648B1/en unknown
- 2018-02-01 MX MX2019009119A patent/MX2019009119A/en unknown
- 2018-02-01 UY UY0001037591A patent/UY37591A/en unknown
- 2018-02-01 SG SG11201906229QA patent/SG11201906229QA/en unknown
- 2018-02-01 AU AU2018215701A patent/AU2018215701B2/en active Active
- 2018-02-01 MY MYPI2019003816A patent/MY194997A/en unknown
-
2019
- 2019-07-29 CO CONC2019/0008209A patent/CO2019008209A2/en unknown
- 2019-07-29 EC ECSENADI201954235A patent/ECSP19054235A/en unknown
- 2019-07-30 CL CL2019002144A patent/CL2019002144A1/en unknown
- 2019-07-30 PH PH12019501773A patent/PH12019501773A1/en unknown
- 2019-07-31 MX MX2022011732A patent/MX2022011732A/en unknown
-
2023
- 2023-02-03 US US18/164,519 patent/US20240092918A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906229QA (en) | Anti-ccr7 antibody drug conjugates | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201808619QA (en) | Nucleic acid-polypeptide compositions and uses thereof | |
SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201906525SA (en) | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201805592RA (en) | Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor | |
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof |